Literature DB >> 22605589

Fatal cumulative toxicities of HAART in a stable, AIDS-free, HIV-infected patient.

Julien Saison1, Laurent Cotte, Christian Chidiac, Tristan Ferry.   

Abstract

The authors describe the case of fatal cumulative toxicities in a 58-year-old AIDS-free, HIV-infected patient, who successively developed under highly active antiretroviral therapy (HAART): severe lipodystrophy, complicated osteoporosis, complicated non-cirrhotic portal hypertension of the liver (with ascites, portal thrombosis, oesophageal varices and protein-losing enteropathy) due to nodular regenerative hyperplasia. These cumulative HAART-related toxicities led to death, despite symptomatic treatment and the switch of antiretrovirals (especially didanosine) putatively involved in the process in these drug-mediated diseases. As morbidity and mortality in HIV infection continue to improve, it appears important to recognise such rare HAART-associated toxicities. This case illustrates the absolute necessity of investigating the long-term side effects of HAART in HIV infection, particularly in patients treated with first generation molecules. The switch strategy (switching old molecules to newer ones) is crucial in case of severe suspected toxicity and has to be discussed in asymptomatic patients largely exposed to first generation molecules, in order to prevent long-term toxicity.

Entities:  

Mesh:

Year:  2012        PMID: 22605589      PMCID: PMC3316843          DOI: 10.1136/bcr.10.2011.4905

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  23 in total

1.  Nodular regenerative hyperplasia of the liver.

Authors:  P E STEINER
Journal:  Am J Pathol       Date:  1959 Sep-Oct       Impact factor: 4.307

2.  Is portal hypertension associated with protein-losing enteropathy?

Authors:  Philippos Georgopoulos; Craig Mowat; Donald C McMillan; Kathleen Kingstone; Subrata Ghosh; Adrian J Stanley
Journal:  J Gastroenterol Hepatol       Date:  2005-01       Impact factor: 4.029

Review 3.  Antiretroviral drugs and liver injury.

Authors:  Vincent Soriano; Massimo Puoti; Pilar Garcia-Gascó; Juergen K Rockstroh; Yves Benhamou; Pablo Barreiro; Barbara McGovern
Journal:  AIDS       Date:  2008-01-02       Impact factor: 4.177

4.  A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

Authors:  Graeme J Moyle; Caroline A Sabin; Jonathan Cartledge; Margaret Johnson; Edmund Wilkins; Duncan Churchill; Philip Hay; Ade Fakoya; Maurice Murphy; George Scullard; Clifford Leen; Geraldine Reilly
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

Review 5.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.

Authors:  Todd T Brown; Roula B Qaqish
Journal:  AIDS       Date:  2006-11-14       Impact factor: 4.177

6.  A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients.

Authors:  Mariagrazia Tateo; Mylène Sebagh; Marie-Pierre Bralet; Elina Teicher; Daniel Azoulay; Vincent Mallet; Stanislas Pol; Denis Castaing; Didier Samuel; Jean-Charles Duclos-Vallée
Journal:  Liver Transpl       Date:  2008-08       Impact factor: 5.799

7.  Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients.

Authors:  Vincent O Mallet; Aditi Varthaman; Dominique Lasne; Jean-Paul Viard; Hervé Gouya; Delphine Borgel; Sébastien Lacroix-Desmazes; Stanislas Pol
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

8.  FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables.

Authors:  Giovanni Lucignani; Eva Orunesu; Miriam Cesari; Katia Marzo; Michela Pacei; Giulia Bechi; Andrea Gori; Sabrina Gaito; Mario Clerici; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-11       Impact factor: 9.236

9.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

Authors:  Krishnan Bhaskaran; Osamah Hamouda; Mette Sannes; Faroudy Boufassa; Anne M Johnson; Paul C Lambert; Kholoud Porter
Journal:  JAMA       Date:  2008-07-02       Impact factor: 56.272

10.  Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.

Authors:  Helen Kovari; Bruno Ledergerber; Ulrich Peter; Markus Flepp; Josef Jost; Patrick Schmid; Alexandra Calmy; Nicolas J Mueller; Beat Muellhaupt; Rainer Weber
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

View more
  2 in total

1.  Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy.

Authors:  Siddappa N Byrareddy; James Arthos; Claudia Cicala; Francois Villinger; Kristina T Ortiz; Dawn Little; Neil Sidell; Maureen A Kane; Jianshi Yu; Jace W Jones; Philip J Santangelo; Chiara Zurla; Lyle R McKinnon; Kelly B Arnold; Caroline E Woody; Lutz Walter; Christian Roos; Angela Noll; Donald Van Ryk; Katija Jelicic; Raffaello Cimbro; Sanjeev Gumber; Michelle D Reid; Volkan Adsay; Praveen K Amancha; Ann E Mayne; Tristram G Parslow; Anthony S Fauci; Aftab A Ansari
Journal:  Science       Date:  2016-10-14       Impact factor: 47.728

Review 2.  The Role of Integrin α4β7 in HIV Pathogenesis and Treatment.

Authors:  James Arthos; Claudia Cicala; Fatima Nawaz; Siddappa N Byrareddy; Francois Villinger; Philip J Santangelo; Aftab A Ansari; Anthony S Fauci
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.